Yin Li1, Ke-Ping Xu2, Dong Jiang3, Jun Zhao3, Jin-Feng Ge3, Shi-Ying Zheng3. 1. Department of Thoracic Surgery, Tumor Hospital of Henan Zhengzhou 450008, Henan Province, China. 2. Department of Thoracic Surgery, Huai'an First People's Hospital, Nanjing Madical University Huaian, 223300, Jiangsu Province, China. 3. Department of Cardio-Thoracic Surgery, First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu Province, China.
Abstract
OBJECTIVE: Lack of surface Fas expression is a main route for apoptotic resistance which is considered an important mechanism of tumorigenesis and tumor progression. Fas and FasL expression in 110 non-small cell lung carcinomas (NSCLCs) were investigated to evaluate their roles in pulmonary carcinogenesis and to examine the clinicopathologic significance of Fas expression with its relationship with p53 and bcl-2 over- expression. METHODS: Immunohistochemical analysis using tissue microarray demonstrated that a large proportion of NSCLC patients (60%) showed lack of membranous Fas expression. The Fas-negative cases revealed the significantly lower survival rate than Fas-positive ones. Also, the loss of Fas receptor expression was found more frequently in advanced stage and higher nodal status. FasL protein was increased in most NSCLCs (89%) compared to normal lungs. RESULTS: p53 and bcl-2 overexpression showed no association with Fas expression. Conclusively, reduced membranous Fas expression as a mechanism of apoptotic resistance is considered to play an important part of the pulmonary carcinogenesis, which may predict poor survival and have a negative prognostic influence. CONCLUSION: Increased FasL expression is thought to be a basis for the immune evasion in NSCLCs. The rare bcl-2 overexpression suggests that this anti-apoptotic protein is unlikely to play a role in the apoptotic resistance of NSCLCs.
OBJECTIVE: Lack of surface Fas expression is a main route for apoptotic resistance which is considered an important mechanism of tumorigenesis and tumor progression. Fas and FasL expression in 110 non-small cell lung carcinomas (NSCLCs) were investigated to evaluate their roles in pulmonary carcinogenesis and to examine the clinicopathologic significance of Fas expression with its relationship with p53 and bcl-2 over- expression. METHODS: Immunohistochemical analysis using tissue microarray demonstrated that a large proportion of NSCLCpatients (60%) showed lack of membranous Fas expression. The Fas-negative cases revealed the significantly lower survival rate than Fas-positive ones. Also, the loss of Fas receptor expression was found more frequently in advanced stage and higher nodal status. FasL protein was increased in most NSCLCs (89%) compared to normal lungs. RESULTS:p53 and bcl-2 overexpression showed no association with Fas expression. Conclusively, reduced membranous Fas expression as a mechanism of apoptotic resistance is considered to play an important part of the pulmonary carcinogenesis, which may predict poor survival and have a negative prognostic influence. CONCLUSION: Increased FasL expression is thought to be a basis for the immune evasion in NSCLCs. The rare bcl-2 overexpression suggests that this anti-apoptotic protein is unlikely to play a role in the apoptotic resistance of NSCLCs.
Authors: L Boldrini; P Faviana; F Pistolesi; S Gisfredi; D Di Quirico; M Lucchi; A Mussi; C A Angeletti; F Baldinotti; A Fogli; P Simi; F Basolo; G Fontanini Journal: Oncogene Date: 2001-10-04 Impact factor: 9.867
Authors: L Boldrini; P Faviana; S Gisfredi; D Di Quirico; M Lucchi; A Mussi; C A Angeletti; F Baldinotti; A Fogli; P Simi; F Basolo; F Pingitore; G Fontanini Journal: Int J Oncol Date: 2002-01 Impact factor: 5.650
Authors: A Hoos; M J Urist; A Stojadinovic; S Mastorides; M E Dudas; D H Leung; D Kuo; M F Brennan; J J Lewis; C Cordon-Cardo Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307
Authors: D Munsch; R Watanabe-Fukunaga; J C Bourdon; S Nagata; E May; E Yonish-Rouach; P Reisdorf Journal: J Biol Chem Date: 2000-02-11 Impact factor: 5.157
Authors: T Fukazawa; T Fujiwara; Y Morimoto; J Shao; M Nishizaki; Y Kadowaki; A Hizuta; L B Owen-Schaub; J A Roth; N Tanaka Journal: Oncogene Date: 1999-04-01 Impact factor: 9.867
Authors: M Mottolese; S Buglioni; C Bracalenti; M A Cardarelli; L Ciabocco; D Giannarelli; C Botti; P G Natali; A Concetti; F M Venanzi Journal: Int J Cancer Date: 2000-03-20 Impact factor: 7.396
Authors: Isabelle Viard-Leveugle; Sylvie Veyrenc; Lars E French; Christian Brambilla; Elisabeth Brambilla Journal: J Pathol Date: 2003-10 Impact factor: 7.996
Authors: Vincenzo Esposito; Alfonso Baldi; Giuseppina Liuzzi; Giuseppe Tonini; Bruno Vincenzi; Paolo Persichetti; Mario Santini; Vincenzo Ambrogi; Tommaso Claudio Mineo; Vincenzo Montesarchio; Ernst Wolner; Feliciano Baldi; Angela M Groeger Journal: Anticancer Res Date: 2003 Nov-Dec Impact factor: 2.480